From a low of .58 on the 11th to .64 today, I'd say the runup into earnings has started already! I think it's starting to get exciting. Hold your shares, this is going to be IGXT's year to go ballistic!
Horse, you say "if we drop below $3 this week" you will pick up your "last 8k shares". We've been below $3.00 since September 19th, probably 65% of that time sub-$3. Hard to believe, but true. Today we had an early spike up, but it was met with a cascade of shares being shorted, another push down orchestrated by shorts. When is this going to end? I think we are right close now, the Company will have to give us the PR that will unlock the value and rock the shorts hard.
Great news, this Company rocks! I reviewed the new corporate presentation on the website this weekend, very impressive, love how they execute and deliver.
It's one thing to be nominated, quite another to WIN it. This speaks volumes, purely an investor conference, now word is getting out and others are learning what we've known here for quite some time. They won't be able to get enough of it, shares are headed much higher.
Ha! Shorts, an afterthought, they are headed toward ruin here. Toasted, black crumbs scattered!
I too am looking, good question, I have my theories, sorry no one answered. I am going to invest small as I expect continued share price recovery and want some of that action.
We may have reason to test that all-time high this week should we have another week of continued positive sentiment following last week's record closing highs in the major indexes. If not, we could decouple and chart our own path, will be interesting going forward nonetheless. With RSi being reset lower after Friday's lower close, I feel optimistic and think the odds favor HZNP having a strong week ahead!
Osiris should acquire HART with current market cap of $23M Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product the HART-Trachea is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our HART-Trachea technology has been used in six human trachea transplants to date approved under compassionate use exemptions but none of our products are yet approved by a government regulatory authority for marketing. On November 1 2013 HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience who has licensed the right to use such trademark from Harvard University.
They have no clue about ants in the dungeon, but they have conviction this one has huge upside with strong prospects for a buyout!
HART did an offering last week at $1.75, I bought shares at 2.19 and am up 38% in 2 days. They use stem cells over a scaffold to engineer a replacement trachea so patient doesn't need immuno-suppressant therapy since stem cells are taken from patient needing the surgery and trachea.
"I have examined a few patients with DMD..."
Are you a medical doctor? What is your area of expertise?
Y is not already approved until they are unequivocally approved which includes manufacturing. Ask me, after two CRL's as a shareholder, it isn't.